Zusammenfassung
Ausgehend von der ursprünglich pathophysiologisch begründeten Behandlungsbedürftigkeit schwerer, genetisch bedingter Fettstoffwechselstürungen wurde der therapeutische Nutzen einer lipidsenkenden Arzneitherapie eingehend untersucht. Zahlreiche angiographische und klinische Studien belegen heute, daß ihr Einsatz die Kriterien Evidenz-basierter Medizin bei Patienten mit erhöhtem kardiovaskulären Risiko erfüllt. Weiterhin verbessern lipidsenkende Maßnahmen relevant die Prognose nach Herztransplantation (Kobashigawa et al. 1995, Jaeger et al. 1997).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (1999): Empfehlungen zur Therapie von Fettstoffwechselstörungen. Arzneiverordnung in der Praxis, Sonderheft 1, 2. Aufl.: 1–16
Brown G., Albers J.J., Fisher L.D., Schaefer S.M, Lin J.T. et al. (1990): Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323: 1289–1299.
Crouse J.R. 3rd, Byington R.P., Bond M.G., Espeland M.A., Craven T.E. et al. (1995): Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 75: 455–459.
Davies M.J. (1996): Stability and instability: two faces of coronary atherosclerosis. Circulation 94: 2013–2020.
Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R. et al. (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterollevels. JAMA 279: 1615–1622.
Enbergs A., Liese A., Heimbach M., Kerber S., Scheid H.H. et al. (1997): Sekundärprävention der koronaren Herzkrankheit auf dem Prüfstand. Ergebnisse der EUROASPIRE-Studie in der Region Münster. Z. Kardiol. 86: 284–291.
Ericsson C.G., Hamsten A., Nilson J., Grip L., Svane B., De Faire U. (1996): Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849–853.
EUROASPIRE Study Group (1997): EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur. Heart J. 18: 1569–1582.
Helsinki Heart Study (1987): Primary-prevention trial with gemfibrozil in middleaged men with dyslipidemia. N. Engl. J. Med. 317: 1237–1245.
Jaeger B.R., Meiser B., Nagel D., Überfuhr P., Thiery J. et al. (1997): Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation (suppl 11): II–154–II–158.
Kobashigawa J.A., Katznelson S., Laks H. (1995): Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333: 621–627.
Levine G.N., Keaney J.E, Vita J.A. (1995): Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332: 512–522.
Lipid Research Clinics Program (1984): tLipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365-374.
Pearson T.A. (1998): Lipid-Iowering therapy in low risk patients. JAMA 279: 1659–1661.
Pyörälä K., DeBacker G., Graham I., Pole-Wilson P., Wood D. (1994): Prevention of coronary heart disease in clinical practice. Eur. Heart J. 15: 1300–1331.
Pyörälä K., Pedersen R.T., Kjekshus J., Faergeman 0., Olsson A.G. et al. (1997): Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614–620.
Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D. et al. (1996): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterollevels. N. Engl. J. Med. 335: 1001–1009.
Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterollowering in 4444 patients with coronary he art disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R. et al. for the West of Scotland Coronary Prevention Study Group (1995): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301–1307.
The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group (1998): Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339. 1349–1357.
Witztum J.L. (1996): Drugs used in the treatment of hyperlipoproteinemias. In: Hardman J.G. et al. (eds.): Goodman & Gilman’s The pharmacological basis of therapeutics, 9th ed., McGraw-Hill, New York, pp. 875–897.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Klose, G., Schwabe, U. (2000). Lipidsenkende Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57215-9_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-57215-9_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66376-8
Online ISBN: 978-3-642-57215-9
eBook Packages: Springer Book Archive